Driven by a team of fast-moving entrepreneurs, management leaders, and industry-recognized horticulturists, Invictus MD is powering the future of the legal cannabis industry.
Since going public in 2014, Invictus MD has grown through early acquisitions and rapid business development to what it is today. With our focus completely on regulated cannabis production, we now manage and operate several licensed facilities across Canada with access to over 250 acres of cultivation space.
All our properties revolve around our core initiative to build out a dominant production profile that can support a wide variety of high-quality strains. With the proper care and attention to detail, we are dedicated to continuously growing with this new industry in an honest, transparent and socially-responsible way.
TSX VENTURE: IMH
UNITED STATES OTC: IVITF
FRANKFURT STOCK EXCHANGE: 8IS1
Large Canadian Footprint of cannabis real estate
We own more than 250 acres of buildable property across the country, allowing for millions of sq. ft. of canopy space as demand dictates.
A one million dollar dividend was paid out in 2016, representing the first ever dividend paid out by a cannabis company.
Strong production profile
By focusing on expanding our production capability, we are forecasted to produce in excess of 50,000 kgs by 2020.
Optimized from the ground up
With presence in Alberta and Ontario, all of our facilities are designed and maintained for optimal plant growth. Site-specific conditions such as climate, humidity, and fresh water supply is leveraged for their passive benefits, resulting in a highly-efficient cultivation system with low operational costs.
Our platform includes ancillary products such as plant nutrients and fertilizers, giving us direct control over every element of the growing process. Having this visibility is a crucial component to our ability to produce a safe and organic product, time and time again.
Our cultivation methodology combines proven agricultural techniques with the advantages of automation and technology. Conditions that are critical for healthy plant growth—temperature, humidity, carbon dioxide levels—are constantly monitored and optimized by an autonomous system. This mitigates risk of human error while ensuring that each facilities remain lean in operation.
From clone to bud, every equipment and system design has been engineered to ensure consistent growth, high quality yields, and competitive cost per gram.
No detail is too small. We obsessively care over every step of the cultivation process.
DOWNLOAD OUR INVESTOR DECK
There’s much more information on our team, production properties, and our projected growth curve with the timing of a recreational roll-out. It also includes:
- Breakdown of facilities
- Capitalization structure
- Future Harvest performance
- Company road map from going public
- Combined Cannabis Production Profile
- Management & Board of Directors
Echelon Wealth Partners
All analyst coverage is conducted by third parties. As such the content of any analyst coverage should not be considered financial advice or forecasting that is approved or endorsed by Invictus MD Strategies Corp.
Data from the United States about the THC pills marketplace shows new consumers are entering the cannabis market, which is useful news for investors in marijuana Speculation among investors about the potential size of the recreational cannabis market in Canada runs the gamut from wild-eyed to dour, with plenty of room in between. Dour probably misses the […]
As Canada moves closer to introducing legal recreational cannabis, investors in marijuana begin to see the outlines of regulations within the provinces With just months to go until recreational marijuana sales are scheduled to be legal across Canada (on Nov. 29 the House of Commons passed Bill C-45, which legalizes cannabis; now the Senate must […]
Vancouver, BC, November 27, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1), through its interests in two Access to Cannabis for Medical Purposes Regulations (“ACMPR“) license holders, its wholly-owned subsidiary Acreage Pharms Ltd. (“Acreage Pharms”) and its one-third interest in AB Laboratories Inc. (“AB Labs”), continues […]